Sixth Street-backed Caris Life valued at $7.66 billion in strong Nasdaq debut

Caris Life Sciences, backed by Sixth Street, saw its shares jump nearly 29% in its Nasdaq debut, valuing the cancer diagnostic firm at $7.66 billion after raising $494.1 million. The successful IPO, along with other recent listings like Circle and Chime, signals a potential revival in the U.S. IPO market, though the healthcare sector, a typically active segment, has lagged behind finance and technology in IPO activity this year. Despite the positive debut, Caris' valuation remains slightly below its $7.83 billion valuation from a 2021 funding round.

Analysis

Caris Life Sciences (CAI.O) executed a strong Nasdaq debut, with shares rising nearly 29% from their $21 offer price to open at $27, achieving a valuation of $7.66 billion and raising $494.1 million. This successful listing, alongside other recent IPOs like Circle (CRCL.N) and Chime (CHYM.O), signals a potential revitalization of the U.S. IPO market in 2025, which had a slow start to the year. However, this IPO market strength is notably concentrated in the finance and technology sectors, which constituted nearly 70% of new flotations as of June 17, 2025, according to Dealogic data, whereas the healthcare sector, typically a significant contributor to IPO activity, accounted for only 5%. Despite Caris's positive reception, its debut valuation is slightly below the $7.83 billion achieved in a 2021 funding round led by Sixth Street, suggesting some market recalibration. Caris, a company utilizing artificial intelligence for personalized cancer treatment plans, represents an innovative player, but its success is viewed by analysts like Matt Kennedy of Renaissance Capital as insufficient on its own to resolve the broader challenges facing the biotech sector, the main engine for U.S. healthcare IPOs.

Key Decisions for Investors

• Investors should acknowledge the improving sentiment in the U.S. IPO market, particularly within the technology and finance sectors, but remain discerning about the broader applicability of this trend.
• Exercise continued caution regarding the healthcare and biotech IPO landscape; Caris Life Sciences' successful debut may not signal an immediate, widespread recovery for this specific segment.
• Monitor Caris Life Sciences' post-IPO performance closely, considering its current valuation relative to its 2021 private market valuation, as an indicator of market appetite for growth-stage diagnostic companies.
• Consider targeted exposure to companies leveraging advanced technologies like AI in healthcare, exemplified by Caris, but weigh this against the prevailing headwinds in the healthcare IPO sector.